Precision therapies take aim at non-Hodgkin’s lymphoma
Elie Dolgin • Nov 14, 2018
The dramatic success of ibrutinib has created a more hopeful reality for people with lymphoma, as targeted therapies fill the pipeline.
Continue reading here.
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
FDA panel’s green light on glaucoma wearable device offers hope in sight.